

South African centers join Pfizer clinical trial network

13 June 2013 | News | By BioSpectrum Bureau



Singapore: South African-based Synexus' clinical research centers Stanza, Watermeyer and Nyeleti will join Pfizer's worldwide network of Inspire, Investigator Networks, Site Partnerships and Infrastructure for Research Excellence. These sites have now early access to Pfizer's portfolio data and advanced information regarding the clinical trials to be sponsored by Pfizer.

Mr Tebogo Sebata, investigator site development and support lead, Pfizer Global, commented, "We are really delighted that we have been able to identify these sites and add them to our Inspire network. We put in place the Inspire programme so that we can work with the best sites across the world. Centers, which have real expertise in the science of clinical trials, the infrastructure support that is necessary, proven recruitment strategies and the in depth knowledge can help us maximize our development programmes going forward."

Dr Sanet Aspinall, MD, Synexus, South Africa, commented, "We are thrilled to have been invited to become part of the Inspire network. We have had to go through an exhaustive assessment programme that looked at our previous experience, expertise across a range of therapeutic areas, infrastructure and resources and effective recruitment strategies. This is not only excellent for our company but for South Africa as it shows that it is a very good place in which to carry out clinical trials."

Dr Glynis Neagle, chief medical officer, Synexus, concluded that, "We are really focussed on providing our clients with quality patients and data. To do this, we are training our doctors and clinical staff in the medical science of the therapy areas we focus on; cardiovascular, metabolic (diabetes and obesity), bone, respiratory, infectious diseases and CNS (dementia and pain). Our investigators are experts in clinical trials and apply this knowledge to each trial which gives added value to clients."